Estrogen-progestogen replacement therapy and ovarian cancer: An update

European Journal of Cancer Prevention

Volumn 15, Issue 6, 2006, Pages 490-492

  Vecchia, Carlo La ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hormone therapy in menopause; Menopause; Ovarian cancer; Risk

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GESTAGEN;

ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ESTROGEN THERAPY; FOLLOW UP; HORMONAL CARCINOGENESIS; HUMAN; NULLIPARA; ORAL CONTRACEPTION; OVARY CANCER; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RISK;

EID: 33751033828     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000205026.14515.de     Document Type: Article

References (24)

1. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. (2003). Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290:1739-1748.
2. Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C (2001). Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285:3089.
3. Bray F, Loos AH, Tognazzo S, La Vecchia C (2005). Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 113:977-990.
4. Coughlin SS, Giustozzi A, Smith SJ, Lee NC (2000). A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53:367-375.
5. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C (2003). Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105:408-412.
6. Garg PP, Kerlikowske K, Subak L, Grady D (1998). Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472-479.
7. Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, et al. (2004). Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164:2253-2259.
8. IARC Monographs on the evaluation of carcinogenic risks to humans (1999). Hormonal contraception and post-menopausal hormonal therapy. Vol. 72. France: IARC Lyon.
9. Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E, Norwegian-Swedish Women's Lifestyle and Health Cohort Study (2004). Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 90:1386-1391.
10. La Vecchia C (2004). Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast 13:515-518.
11. La Vecchia C, Brinton LA, McTiernan A (2001). Menopause, hormone replacement therapy and cancer. Maturitas 39:97-115.
12. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. (2002). Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334-341.
13. Mills PK, Riordan DG, Cress RD (2004). Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. Gynecol Oncol 95:215-225.
14. Mills PK, Riordan DG, Cress RD (2005). Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29:124-132.
15. Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos D, Parazzini F, et al. (1999). Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 80:848-851.
16. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004). Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82:186-195.
17. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, et al. (1999). Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81:559-563.
18. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. (2001). Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83:575-585.
19. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. (2002). Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497-504.
20. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001). Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460-1465.
21. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M (1999). Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59:3658-3662.
22. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB (2002). Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86:118-123.
23. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 291:1701-1712.
24. Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288:321-333.